The researchers showed “super antibodies” from the man’s blood prevented toxic damage from neurotoxins found in the venoms of 19 different snake species. Scientists in the United States have ...

For hematologic cancers, the past decade was marked by the rise of alternative immunotherapies such as antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric ...

("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, ...

1Tumor Immune Analysis Core, Office of Research & Development, Taipei Medical University, Taipei, Taiwan.

Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint ...

The pipeline of the company includes two antibodies designed to tackle various autoimmune conditions. Credit: SaiArLawKa2 / Shutterstock. Swiss-based immunology company Granite Bio has secured $100m ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting several autoimmune diseases. The funding consists of a $30 million series ...

SAN FRANCISCO--(BUSINESS WIRE)--Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer ...

Veraxa, founded on scientific discoveries at the European lab, said it’s recently widened its scope to focus on two hot areas in cancer research: antibody-drug conjugates and T cell engagers. Veraxa ...

Full results from the trial evaluating Akeso’s first-in-class PD-1/VEGF bispecific antibody are expected to be presented later this year at a medical conference. 1 "The interim analysis results from ...